← Oncology Approval Tracker

FDA DECISION ·

Pedmark

sodium thiosulfate · Fennec Pharmaceuticals

FDA approvalNew therapyCisplatin-associated hearing loss
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Reduction of cisplatin-related ototoxicity in pediatric patients age one month or older with localized, nonmetastatic solid tumors.

LAMPGEN ANALYSIS

Why it matters

This action addresses a potentially permanent treatment complication in a defined pediatric group.

What research teams should watch

Coordinate dose timing relative to cisplatin and establish baseline and serial audiology assessments.

PRIMARY RECORDS

Sources